ArticleCancer biology & therapy2013
FADD the bad in head and neck cancer.
Article in Cancer biology & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- CDCSI: a machine learning-based interpretable cell death and cellular senescence index for prognosis improvement, immune landscape characterization, and therapeutic response prediction in head and neck squamous cell carcinoma.Frontiers in immunology · 2026Article
- Establishment and validation of a recurrent prediction model for glioma: extrinsic apoptotic molecules FADD and CASP8 are closely associated with glioma recurrence.BMC immunology · 2025Article
- MYEOV with High Frequencies of Mutations in Head and Neck Cancers Facilitates Cancer Cell Malignant Behaviors.Biochemical genetics · 2024Article
- Identification of autophagy-related biomarker and analysis of immune infiltrates in oral carcinoma.Journal of clinical laboratory analysis · 2022Article
- Overexpression of FADD and Bcl-XS proteins as novel prognostic biomarkers for surgically resected non-small cell lung cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- MVisAGe Identifies Concordant and Discordant Genomic Alterations of Driver Genes in Squamous Tumors.Cancer research · 2018Article
- Integrating omics data and protein interaction networks to prioritize driver genes in cancer.Oncotarget · 2017Article
- MiR-7a is an important mediator in Fas-associated protein with death domain (FADD)-regulated expression of focal adhesion kinase (FAK).Oncotarget · 2016Article
- Decreased expression of APAF-1 and increased expression of cathepsin B in invasive pituitary adenoma.OncoTargets and therapy · 2015Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
It has been known for many years that the protein Fas-associated death domain (FADD) is an essential protein forming the apical portion of the extrinsic apoptosis pathway that permits association of death receptors, e.g., CD95, DR4, DR5 with pro-caspases 8 and 10, thereby facilitating caspase activation (e.g., ref. 1, and references therein). It is also known that FADD can recruit other proteins to regulate NFκB and MAPK pathways which in turn can promote proliferation and cell cycle progression. In NSCLC high expression of FADD has been associated with shorter survival times and lymph node metastasis or oral cancer and worse survival, and the present manuscript in head and neck cancer demonstrates similar findings with respect to lymph node metastasis and survival.(2,3)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.